Patent Assignment
Reel/Frame 070703/0524
Release of Security Interest
Recorded: 2025-04-01
Pages: 12
Assignor
JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Executed: 2025-03-28
Assignee
EAGLE PHARMACEUTICALS, INC.
50 TICE BLVD, SUITE 315, WOODCLIFF LAKE, NEW JERSEY, 07677
Covered Properties
(70)
Alcohol Free Formulation of Argatroban
Alcohol Free Formulation of Argatroban
Ready-To-Use Bivalirudin Compositions
Patent:
7,803,762 →
Application:
12/545,036 →
Ready-To-Use Bivalirudin Compositions
Patent:
7,713,928 →
Application:
12/563,821 →
Formulations of Daptomycin
Formulations of Bendamustine
Alcohol Free Formulation of Argatroban
Application:
13/618,532 →
Publication:
US 2013/0023559
Formulations of Bendamustine
Application:
13/767,672 →
Publication:
US 2013/0210879
Pharmaceutical Compositions Containing Pemetrexed Having Extended Storage Stability
Formulations of Bendamustine
Method of Treating Bendamustine-Responsive Conditions in Patients Requiring Reduced Volumes for Administration
Formulations of Bendamustine
Aqueous Buffer-Free Bivalirudin Compositions
Application:
14/711,359 →
Publication:
US 2015/0328317
Formulations of Bendamustine
Method of Treating Bendamustine-Responsive Conditions in Patients Requiring Reduced Volumes for Administration
Formulations of Bendamustine
Aqueous Buffer-Free Bivalirudin Compositions
Application:
14/982,813 →
Publication:
US 2016/0106840
Formulations of Bendamustine
Formulations of Bendamustine
Formulations of Bendamustine
Formulations of Bendamustine
Pemetrexed Formulations
Application:
15/048,416 →
Publication:
US 2017/0239250
Formulations of Bendamustine
Formulations of Bendamustine
Vial with Collar Label
Patent:
676,572 →
Application:
29/403,209 →
Formulations of Bendamustine
Formulations of Bendamustine
Fulvestrant Formulations and Methods of Their Use
Application:
16/099,265 →
Publication:
US 2019/0134059
Pemetrexed Formulations
Application:
16/297,125 →
Publication:
US 2019/0201405
Fulvestrant Formulations
Formulations of Bendamustine
Fulvestrant Formulations
Application:
16/508,741 →
Publication:
US 2020/0188411
Apparatus for mm-wave radiation generation utilizing whispering gallery mode resonators
Application:
15/588,002 →
Publication:
US 2017/0325326
Dantrolene Formulations and Methods of Their Use
Application:
17/052,572 →
Publication:
US 2021/0236467
Formulations of Bendamustine
Application:
17/679,883 →
Publication:
US 2022/0323584
Formulations of Bendamustine
Application:
17/740,990 →
Publication:
US 2022/0265829
Formulations of Bendamustine
Application:
17/412,623 →
Publication:
US 2021/0393594
Fulvestrant Formulations
Fulvestrant Formulations and Methods of Their Use
Fulvestrant Formulations and Methods of Their Use
Methods of Using Dantrolene to Treat Nerve Agent Exposure
Application:
17/540,878 →
Publication:
US 2022/0087980
Pemetrexed Formulations
Methods of Treating Sars-Cov-2 Infections
Application:
17/995,602 →
Publication:
US 2023/0144719
Methods of Treating Severe Acute Respiratory Syndrome
Methods of Treating Coronavirus Infections
Application:
17/995,606 →
Publication:
US 2023/0143775
Methods of Treating Viral Infections
Application:
17/995,608 →
Publication:
US 2023/0149364
Fulvestrant Formulations
Application:
17/022,574 →
Publication:
US 2021/0260076
Fulvestrant Formulations
Application:
17/819,726 →
Publication:
US 2022/0387446
Pemetrexed Formulations
Application:
17/898,558 →
Publication:
US 2023/0000874
Pemetrexed Formulations
Application:
17/898,637 →
Publication:
US 2022/0409623
Pemetrexed Formulations
Application:
17/898,984 →
Publication:
US 2022/0409624
Formulations of Bendamustine
Application:
18/498,259 →
Publication:
US 2024/0075013
Formulations of Bendamustine
Formulations of Bendamustine
Formulations of Bendamustine
Application:
18/296,290 →
Publication:
US 2023/0285563
Formulations of Bendamustine
Application:
18/296,268 →
Publication:
US 2023/0241218
Fulvestrant Formulations and Methods of Their Use
Fulvestrant Formulations
Application:
18/506,633 →
Publication:
US 2024/0082264
Pemetrexed Formulations
Application:
18/470,621 →
Publication:
US 2024/0009198
Pemetrexed Formulations
Pemetrexed Formulations
Application:
18/456,772 →
Publication:
US 2023/0414623
Fulvestrant Compositions and Methods of Their Use
Application:
62/420,555 →
Fulvestrant Formulations
Application:
62/332,842 →
Fulvestrant Formulations
Fulvestrant Formulations
Fulvestrant formulations
Formulations of Bendamustine
Formulations of Bendamustine
Aqueous Buffer-Free Bivalirudin Compositions
PCT:
PCT/US2015/030581 ↗
Pemetrexed Formulations
PCT:
PCT/US2016/018703 ↗
Related Assignments
(23)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Sep 26, 2007
From: PALEPU, NAGESWARA R.
To: SCIDOSE LLC
Reel/Frame 019937/0928 →
Assignment of Assignor's Interest
Dec 14, 2007
From: SCIDOSE, LLC
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 020246/0476 →
Assignment of Assignor's Interest
Dec 14, 2007
From: PALEPU, NAGESH R.
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 020246/0357 →
Assignment of Assignor's Interest
Aug 21, 2009
From: PALEPU, NAGESH, DR.; MOTHERAM, RAJESHWAR, DR.; SHAH, PRAFUL, DR.; KRISHNA, GOPAL, DR.
To: THE MEDICINES COMAPNY; EAGLE PHARMACEUTICALS, INC.
Reel/Frame 023126/0758 →
Assignment of Assignor's Interest
Jun 8, 2010
From: PALEPU, NAGESH; MOTHERAM, RAJESHWAR; SHAH, PRAFUL; KRISHNA, GOPAL
To: THE MEDICINES COMPANY; EAGLE PHARMACEUTICALS, INC.
Reel/Frame 024492/0434 →
Assignment of Assignor's Interest
Oct 20, 2010
From: PALEPU, NAGESH R.; TEJA, BULUSU BHANU
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 025165/0719 →
Assignment of Assignor's Interest
Mar 9, 2011
From: PALEPU, NAGESH R.; BUXTON, PHILIP CHRISTOPHER
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 025923/0962 →
Assignment of Assignor's Interest
Apr 24, 2014
From: PALEPU, NAGESH R.; BUXTON, PHILIP CHRISTOPHER; SUNDARAM, SRIKANTH
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 032751/0237 →
Assignment of Assignor's Interest
Apr 30, 2014
From: SUNDARAM, SRIKANTH; TARRIFF, SCOTT L.
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 032791/0091 →
Assignment of Assignor's Interest
Apr 30, 2014
From: SUNDARAM, SRIKANTH
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 032791/0599 →
Assignment of Assignor's Interest
Apr 30, 2014
From: PALEPU, NAGESH R.; BUXTON, PHILIP CHRISTOPHER
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 032790/0596 →
Assignment of Assignor's Interest
Feb 25, 2015
From: TARRIFF, SCOTT L.
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 035025/0435 →
Assignment of Assignor's Interest
May 20, 2015
From: EAGLE PHARMACEUTICALS, INC.
To: SCIDOSE, LLC
Reel/Frame 035682/0656 →
License
May 22, 2015
From: EAGLE PHARMACEUTICALS, INC.
To: CEPHALON, INC.
Reel/Frame 035696/0856 →
License
Jun 23, 2015
From: EAGLE PHARMACEUTICALS, INC.
To: CEPHALON, INC.
Reel/Frame 035887/0475 →
Assignment of Assignor's Interest
Sep 15, 2015
From: CHEN, FENG-JING; KRILL, STEVEN L.
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 036569/0069 →
Assignment of Assignor's Interest
Dec 29, 2015
From: SCIDOSE, LLC
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 037378/0274 →
Security Interest
Jan 26, 2017
From: EAGLE PHARMACEUTICALS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 041095/0554 →
Assignment of Assignor's Interest
Dec 28, 2017
From: CHEN, FENG-JING; KRILL, STEVEN L.
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 044499/0001 →
Assignment of Assignor's Interest
Dec 17, 2018
From: THE MEDICINES COMPANY
To: SANDOZ INC.
Reel/Frame 047794/0061 →
Assignment of Assignor's Interest
Oct 19, 2022
From: PALEPU, NAGESH R.; BUXTON, PHILIP CHRISTOPHER
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 061473/0077 →
Security Interest
May 14, 2025
From: EAGLE SUBI LLC, A DELAWARE CORPORATION
To: LSI FINANCING LLC
Reel/Frame 071275/0866 →
Grant of Security Interest
Feb 18, 2026
From: EAGLE PHARMACEUTICALS, INC
To: ANKURA TRUST COMPANY, LLC.
Reel/Frame 074849/0457 →